Country: Canada
Language: English
Source: Health Canada
VARICELLA VIRUS LIVE ATTENUATED (OKA/MERCK STRAIN)
MERCK CANADA INC
J07BK01
VARICELLA, LIVE ATTENUATED
1350UNIT
POWDER FOR SOLUTION
VARICELLA VIRUS LIVE ATTENUATED (OKA/MERCK STRAIN) 1350UNIT
SUBCUTANEOUS
1/10X0.5ML
Schedule D
VACCINES
Active ingredient group (AIG) number: 0165422001; AHFS:
APPROVED
2005-07-08
_VARIVAX_ _®_ _ III (varicella virus vaccine, live, attenuated [Oka/Merck])_ _ _ _Page 1 of 28_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION VARIVAX® III (varicella virus vaccine, live, attenuated [Oka/Merck]) Lyophilized powder for subcutaneous injection 1350 plaque forming units (PFU) per 0.5 mL single dose vials of Oka/Merck varicella virus, live, attenuated Active immunizing agent against varicella ATC code: J07BK01 Merck Canada Inc. 16750 route Transcanadienne Kirkland QC Canada H9H 4M7 www.merck.ca Date of Initial Authorization: JUN 19, 2002 Date of Revision: November 28, 2023 SUBMISSION CONTROL NUMBER: 276760 _ _ _VARIVAX_ _®_ _ III (varicella virus vaccine, live, attenuated [Oka/Merck])_ _ _ _Page 2 of 28_ RECENT MAJOR LABEL CHANGES 8 Adverse Reactions, 8.5 Post-Market Adverse Reactions 06/2023 9 Drug Interactions, 9.4 Drug-Drug Interaction 09/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics (Less than 1 year old) ............................................................................. 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ................................. Read the complete document